Dynamite News
Protein discovery may help solve prostate cancer medicine resistance
Researchers discovered that a receptor protein called CHRM1 plays an important role in prostate cancer cells' resistance to docetaxel, a routinely used chemotherapeutic treatment to treat advanced cancer that has progressed beyond the prostate. Read further on Dynamite News:
Washington DC [US]: Researchers discovered that a receptor protein called CHRM1 plays an important role in prostate cancer cells' resistance to docetaxel, a routinely used chemotherapeutic treatment to treat advanced cancer that has progressed beyond the prostate.
The revelation opens the door to new treatments that may overcome this resistance. This could eventually help to lengthen the lives of people suffering from prostate cancer, which is one of the main causes of cancer deaths among men.
Read This Also: Loss of cells in pancreas in elderly can cause age-related diabetes
Led by a team of scientists at Washington State University, the study showed that blocking CHRM1 in resistant prostate cancer cell lines and an animal model based on patient-derived resistant tissue restored docetaxel's ability to kill cells and stop tumor growth. The researchers did this by using dicyclomine, a drug that selectively inhibits CHRM1 activity. Dicyclomine is already on the market as a generic drug and is currently used to treat symptoms of irritable bowel syndrome.
"The effect was pretty dramatic in all the experimental models we tested," said Boyang (Jason) Wu, an associate professor in the WSU College of Pharmacy and Pharmaceutical Sciences and co-senior author on the study. "And because dicyclomine already has a clinical use, this work has immediate translational potential."
Read This Also: Bacterial meningitis can cause neurological damage in children
Published in the journal Cell Reports Medicine, the researchers' findings support clinical testing to confirm whether combined use of docetaxel and dicyclomine could help overcome treatment resistance in prostate cancer patients. Docetaxel resistance can develop in prostate cancer after about six months of treatment.
Chemotherapy drugs like docetaxel are among very few options available to patients with castration-resistant prostate cancer, a lethal form of the disease that no longer responds to hormone therapy.
Wu said this type of combination therapy could also potentially be used for other cancers that are currently being treated with docetaxel, such as breast and lung cancer. It may also be possible to use the same combination strategy with other similar chemotherapy drugs.
In addition to testing resistant cancer cell lines, the research team also tested cells that still responded to docetaxel treatment. They found that using dicyclomine to block CHRM1 in these cells made docetaxel more efficient at killing them. Wu said that this shows that prostate cancer patients could potentially benefit from a combination treatment strategy even before docetaxel resistance develops.
"What this suggests is that the lowest effective dose of docetaxel may be lower when the drug is combined with dicyclomine, compared to when docetaxel is used alone," Wu said. "Being able to use a lower dose could help reduce unwanted side effects and make treatment more manageable for patients." (ANI)